Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice

Santoleri, Fiorenzo; Sorice, Paola; Lasala, Ruggero; Rizzo, Rosa Carmela; Costantini, Alberto

doi:10.1371/journal.pone.0056813

Cited by 43 publications

(51 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recently published retrospective analysis also reported better adherence with nilotinib over dasatinib while using a ratio between received daily dose and prescribed daily dose. 67 In contrast, but confirming the results from Yood and colleagues, 33 2 conference abstracts from the literature search reported a better adherence with dasatinib over nilotinib. 43,45 Among patients receiving second-line CML treatments, those receiving dasatinib (100 mg) had higher rates of adherence using MPR than those receiving nilotinib (800 mg) (75% versus 69%, respectively) from a US retrospective analysis.…”

Section: © F E R R a T A S T O R T I F O U N D A T I O Nsupporting

confidence: 54%

See 1 more Smart Citation

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

Correspondence: Lucien.Noens@uzgent.be BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions was performed and critically appraised. Of the 19 included articles, 9 were retrospective. Average adherence varied from 19% to almost 100% of the proportion of prescribed drug taken, but it was measured through various different methods and within different study groups. Suboptimal adherence was associated with a negative impact on both clinical and economic outcomes. There is a lack of supportive evidence demonstrating a difference in adherence across BCR-ABL inhibitors and even contradictory results between the 2 nd generation inhibitors. Drug-related adverse events and forgetfulness were common reasons for intentional and unintentional non-adherence, respectively, but further research is required to identify additional reasons behind non-adherence or patients at risk of non-adherence. Non-adherence in chronic myeloid leukemia patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. However, this review highlights important existing gaps, reveals inconsistent definitions, and a lack of standardized methods for measuring adherence in chronic myeloid leukemia. All require further investigation. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o nAnalyses statement for systematic reviews. 16 Publication database (EMBASE, PubMed, and Cochrane Library) specific search terms consisted of both single and MeSH terms for the disease, adherence and BCR-ABL inhibitor therapy (Online Supplementary Table S1). The last search was conducted on December 20 th , 2011. Full-text references were provided for the eligible abstracts that were published after completion of the search process and the analyses. In addition, and due to the lack of existing evidence of adherence in CML, clinical and economic conference proceedings were also searched with a time limit of three years. Preliminary inclusion (or exclusion) of a specific study or conference abstract was based on review of the title and abstract by 2 independent reviewers against pre-specified criteria (Table 1). Final inclusion of the study was based on an in-depth review of the full manuscript. Multiple variables were extracted from the articles to answer study objectives (Online Supplementary Table S2). The analysis was descriptive only. Since abstracts in conference pr...

show abstract

Section: © F E R R a T A S T O R T I F O U N D A T I O Nsupporting

confidence: 54%

“…31,33,45,67 Few studies adjusted their estimates by disease severity, 15,18,20,22,24,31,50 but most did not adjust by comorbidities, thereby potentially under-estimating the real impact of adherence.…”

Section: © F E R R a T A S T O R T I F O U N D A T I O Nmentioning

confidence: 99%

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

show abstract

“…nd generation TKIs dasatinib, nilotinib, and bosutinib have since been approved [7], followed by 3 rd generation ponatinib [4,8,9]. Some patients are initially treated with hydroxyurea [4].…”

mentioning

confidence: 99%

“…'the extent of conformity to the recommendations about day to day treatment by the provider with respect to timing, dosage and frequency' [3] is crucial to achieve optimal treatment response [6][7][8]11,12,17,[26][27][28][29][30][31]32]. Yet the fact that CML has become a manageable chronic disease with much improved quality of life (QoL) may challenge adherence [4,8,26].…”

mentioning

confidence: 99%

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Mortensen¹,

Mourek

2017

JHOR

View full text Add to dashboard Cite

With the introduction of tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have obtained survival rates close to normal. It may appear paradoxical, then, that medication adherence is suboptimal in some health care settings. As the first of its kind, this study aimed to explore drivers and barriers to TKI treatment adherence in Danish CML patients. A literature study informed the design of qualitative interviews with 20 patients, individually and in focus groups, focusing on their disease perceptions of CML, their health-related quality of life (QoL) and medication adherence. The study showed that many participants had previously switched treatment due to lacking efficacy or intolerance but most felt their current disease burden was tolerable. Anxiety might, however, resurface if treatment stopped working or with the occurrence of infections or side effects, creating a state of 'fragile peace'. To these patients, their role functioning -as professionals, spouses, parents and grandparents -was crucial to uphold a positive self-image and meaningful life. Whether treatment enabled or hindered this was thus decisive to their QoL and medication adherence. Our participants expressed high adherence rates with only one having intentionally non-adhered due to side effects and poor QoL. Most participants felt well-informed about CML and treatment and privileged to receive specialised personal care from the public health care system acting to motivate their medication adherence. As a novel finding, this study indicates that the prospect of treatment-free remission may positively affect adherence. We suggest this should be explored in future studies.

show abstract

“…In fact, non-adherence represents a problem both for clinical outcome and loss of economic resources for the health system. In literature several methods are reported to calculate the adherence to treatment such as Continuous Measure of Medication Acquisition (CMA) [25]- [27]; Medication Possession Ratio (MPR) [28]- [30]; Medication Refill Adherence (MRA) [31]- [33] [41]. The most utilized methods are MPR and PDC [43].…”

Section: Introductionmentioning

confidence: 99%

Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus

Santoleri¹,

Sorice²,

Lasala³

et al. 2014

Self Cite

View full text Add to dashboard Cite

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice

Cited by 43 publications

References 15 publications

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About